Merit Medical Reports Strong Q1 Earnings and Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy MMSI?
Source: seekingalpha
Merit Medical Systems' stock fell 9.42% as it crossed below the 5-day SMA amid broader market gains.
The company reported strong Q1 2026 earnings with a revenue of $381.9 million, a 7% year-over-year increase, and announced the acquisition of View Point Medical for $140 million, which is expected to significantly enhance its oncology business. Despite these positive developments, the stock's decline suggests sector rotation as investors shift focus.
The strong earnings and strategic acquisition position Merit Medical for future growth, but the stock's current movement indicates a disconnect between market performance and investor sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MMSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MMSI
Wall Street analysts forecast MMSI stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 62.010
Low
90.00
Averages
104.63
High
122.00
Current: 62.010
Low
90.00
Averages
104.63
High
122.00
About MMSI
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merit Medical Systems Reports Strong Q1 2026 Earnings and Strategic Acquisition
- Revenue Growth: Merit Medical reported total revenue of $381.9 million in Q1 2026, reflecting a 7% year-over-year increase, with U.S. sales up 6.8% and international sales up 3%, indicating robust market performance.
- Acquisition Expansion: The company acquired View Point Medical for $140 million, with $90 million paid in cash, which is expected to triple the annual addressable procedure opportunity for its oncology business, enhancing competitive positioning.
- Profitability Improvement: Q1 net income reached $56.7 million, or $0.94 per share, exceeding guidance by $3.7 million, while the non-GAAP operating margin hit 19.7%, marking the highest in the company's history and reflecting effective management execution.
- Future Outlook: The company anticipates total revenue growth of 6.3% to 7.8% for 2026, with non-GAAP EPS projected between $4.01 and $4.15, demonstrating confidence in future growth despite facing tariff and geopolitical risks.
See More
Merit Medical Systems to Release Q1 2026 Financial Results
- Earnings Release Schedule: Merit Medical Systems plans to announce its financial results for the quarter ending March 31, 2026, after market close on April 30, 2026, demonstrating the company's commitment to transparency and investor communication.
- Investor Conference Call: On the same day, Merit will hold an investor conference call at 4:30 p.m. Eastern Time, aimed at sharing financial results and addressing investor inquiries, thereby enhancing investor confidence.
- Company Background: Founded in 1987, Merit focuses on the development, manufacturing, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, and oncology, showcasing its expertise in healthcare technology.
- Global Workforce: Merit employs approximately 7,600 people worldwide, supported by a domestic and international sales force and clinical support team of over 800 individuals, indicating its extensive reach and service capabilities in the global market.
See More
Merit Medical Acquires View Point Medical for $140M
- Acquisition Overview: Merit Medical Systems has acquired View Point Medical for a total transaction value of $140 million, with $90 million paid upfront and $25 million due on the first and second anniversaries of the closing date, thereby enhancing its competitive position in the medical device market.
- Product Innovation Enhancement: View Point Medical manufactures the OneMark Detection Imaging System and OneMark Tissue Markers, which improve tissue localization, allowing surgeons to quickly detect and visualize tissue markers during biopsies, thus enhancing precision in breast cancer surgeries and reducing re-excision rates.
- Future Growth Projections: Merit Medical projects a revenue growth of 6% to 8% for 2026, and this acquisition will help strengthen its global platforms while divesting DualCap to optimize resource allocation and enhance profitability.
- Industry Impact Analysis: This acquisition not only enhances Merit’s product portfolio in the medical technology sector but also has the potential to drive technological advancements in breast cancer treatment by improving surgical precision and reducing patient reoperation risks, highlighting its strategic significance.
See More
Merit Medical Acquires View Point Medical for $140 Million
- Acquisition Overview: Merit Medical Systems has acquired View Point Medical for approximately $140 million, with $90 million paid in cash at closing and two deferred payments of $25 million each scheduled for the first and second anniversaries, enhancing Merit's market position in oncology products.
- Technological Integration Benefits: The acquisition combines View Point's OneMark® Detection Imaging System with Merit's SCOUT® platform, providing a more precise solution for breast tumor localization, expected to support 1.3 million biopsy procedures annually, improving treatment timeliness and accuracy for patients.
- Financial Impact Analysis: The acquisition is projected to contribute revenue of $2 million to $4 million in 2026 but will dilute Merit's non-GAAP earnings per share by approximately $0.05, reflecting short-term financial pressure, while long-term revenue growth is anticipated.
- Market Outlook: Sales of the OneMark system are expected to grow at least 20% annually by 2027, with a 70% non-GAAP gross margin, indicating that while the acquisition may dilute GAAP net income in the short term, it is likely to improve Merit's profitability in the long run.
See More
Medtronic Enters Exclusive Agreement with Merit for BVNA System
- Exclusive Distribution Agreement: Medtronic has signed an exclusive agreement with Merit Medical Systems to launch the FDA-approved ViaVerte system, which is the first BVNA system with a physician-controlled steerable mechanism aimed at treating chronic vertebrogenic lower back pain, significantly enhancing treatment options for patients.
- Product Innovation: The unique design of the ViaVerte system allows physicians to precisely target the basivertebral nerve, thereby improving treatment outcomes and further solidifying Medtronic's leadership in the pain intervention space while providing more effective solutions for chronic pain patients.
- Strengthened Strategic Partnership: This agreement not only expands Medtronic's pain intervention product portfolio but also deepens the ongoing collaboration with Merit, which currently supplies Medtronic with Kyphon Xpander Inflation Syringes and Kyphon KyphoFlex unipedicular steerable balloon catheters used in balloon kyphoplasty procedures.
- Market Impact: By introducing the ViaVerte system, Medtronic enhances its competitiveness in the chronic pain treatment market, which is expected to attract more patients to its innovative treatment options, thereby driving continued growth in the medical technology sector.
See More
Medtronic Enters Exclusive Agreement with Merit Medical
- Innovative Treatment Solution: Medtronic has entered into an exclusive distribution agreement with Merit Medical to offer the FDA-cleared ViaVerte™ basivertebral nerve ablation system, which is the first BVNA system with a physician-controlled steerable mechanism, significantly enhancing treatment options for chronic lower back pain patients.
- Market Demand Response: According to the American Chronic Pain Association, approximately one in three Americans suffer from chronic pain, and the introduction of the ViaVerte™ system will provide these patients with a minimally invasive, same-day outpatient treatment option, addressing the growing market demand.
- Deepening Strategic Partnership: This agreement not only continues the collaboration between Medtronic and Merit but also enhances Medtronic's leadership in the pain intervention field by incorporating Merit's proprietary technology, thereby diversifying its product portfolio.
- Long-term Vision: Paolo Di Vincenzo, president of Medtronic's Neuromodulation division, stated that the addition of this new product will further expand their world-leading position in pain interventions, aiming to provide more effective treatment options for patients and physicians.
See More
Merit Medical Systems Reports Strong Q1 2026 Earnings and Strategic Acquisition
- Revenue Growth: Merit Medical reported total revenue of $381.9 million in Q1 2026, reflecting a 7% year-over-year increase, with U.S. sales up 6.8% and international sales up 3%, indicating robust market performance.
- Acquisition Expansion: The company acquired View Point Medical for $140 million, with $90 million paid in cash, which is expected to triple the annual addressable procedure opportunity for its oncology business, enhancing competitive positioning.
- Profitability Improvement: Q1 net income reached $56.7 million, or $0.94 per share, exceeding guidance by $3.7 million, while the non-GAAP operating margin hit 19.7%, marking the highest in the company's history and reflecting effective management execution.
- Future Outlook: The company anticipates total revenue growth of 6.3% to 7.8% for 2026, with non-GAAP EPS projected between $4.01 and $4.15, demonstrating confidence in future growth despite facing tariff and geopolitical risks.
See More
Merit Medical Systems to Release Q1 2026 Financial Results
- Earnings Release Schedule: Merit Medical Systems plans to announce its financial results for the quarter ending March 31, 2026, after market close on April 30, 2026, demonstrating the company's commitment to transparency and investor communication.
- Investor Conference Call: On the same day, Merit will hold an investor conference call at 4:30 p.m. Eastern Time, aimed at sharing financial results and addressing investor inquiries, thereby enhancing investor confidence.
- Company Background: Founded in 1987, Merit focuses on the development, manufacturing, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, and oncology, showcasing its expertise in healthcare technology.
- Global Workforce: Merit employs approximately 7,600 people worldwide, supported by a domestic and international sales force and clinical support team of over 800 individuals, indicating its extensive reach and service capabilities in the global market.
See More
Merit Medical Acquires View Point Medical for $140M
- Acquisition Overview: Merit Medical Systems has acquired View Point Medical for a total transaction value of $140 million, with $90 million paid upfront and $25 million due on the first and second anniversaries of the closing date, thereby enhancing its competitive position in the medical device market.
- Product Innovation Enhancement: View Point Medical manufactures the OneMark Detection Imaging System and OneMark Tissue Markers, which improve tissue localization, allowing surgeons to quickly detect and visualize tissue markers during biopsies, thus enhancing precision in breast cancer surgeries and reducing re-excision rates.
- Future Growth Projections: Merit Medical projects a revenue growth of 6% to 8% for 2026, and this acquisition will help strengthen its global platforms while divesting DualCap to optimize resource allocation and enhance profitability.
- Industry Impact Analysis: This acquisition not only enhances Merit’s product portfolio in the medical technology sector but also has the potential to drive technological advancements in breast cancer treatment by improving surgical precision and reducing patient reoperation risks, highlighting its strategic significance.
See More
Merit Medical Acquires View Point Medical for $140 Million
- Acquisition Overview: Merit Medical Systems has acquired View Point Medical for approximately $140 million, with $90 million paid in cash at closing and two deferred payments of $25 million each scheduled for the first and second anniversaries, enhancing Merit's market position in oncology products.
- Technological Integration Benefits: The acquisition combines View Point's OneMark® Detection Imaging System with Merit's SCOUT® platform, providing a more precise solution for breast tumor localization, expected to support 1.3 million biopsy procedures annually, improving treatment timeliness and accuracy for patients.
- Financial Impact Analysis: The acquisition is projected to contribute revenue of $2 million to $4 million in 2026 but will dilute Merit's non-GAAP earnings per share by approximately $0.05, reflecting short-term financial pressure, while long-term revenue growth is anticipated.
- Market Outlook: Sales of the OneMark system are expected to grow at least 20% annually by 2027, with a 70% non-GAAP gross margin, indicating that while the acquisition may dilute GAAP net income in the short term, it is likely to improve Merit's profitability in the long run.
See More
Medtronic Enters Exclusive Agreement with Merit for BVNA System
- Exclusive Distribution Agreement: Medtronic has signed an exclusive agreement with Merit Medical Systems to launch the FDA-approved ViaVerte system, which is the first BVNA system with a physician-controlled steerable mechanism aimed at treating chronic vertebrogenic lower back pain, significantly enhancing treatment options for patients.
- Product Innovation: The unique design of the ViaVerte system allows physicians to precisely target the basivertebral nerve, thereby improving treatment outcomes and further solidifying Medtronic's leadership in the pain intervention space while providing more effective solutions for chronic pain patients.
- Strengthened Strategic Partnership: This agreement not only expands Medtronic's pain intervention product portfolio but also deepens the ongoing collaboration with Merit, which currently supplies Medtronic with Kyphon Xpander Inflation Syringes and Kyphon KyphoFlex unipedicular steerable balloon catheters used in balloon kyphoplasty procedures.
- Market Impact: By introducing the ViaVerte system, Medtronic enhances its competitiveness in the chronic pain treatment market, which is expected to attract more patients to its innovative treatment options, thereby driving continued growth in the medical technology sector.
See More
Medtronic Enters Exclusive Agreement with Merit Medical
- Innovative Treatment Solution: Medtronic has entered into an exclusive distribution agreement with Merit Medical to offer the FDA-cleared ViaVerte™ basivertebral nerve ablation system, which is the first BVNA system with a physician-controlled steerable mechanism, significantly enhancing treatment options for chronic lower back pain patients.
- Market Demand Response: According to the American Chronic Pain Association, approximately one in three Americans suffer from chronic pain, and the introduction of the ViaVerte™ system will provide these patients with a minimally invasive, same-day outpatient treatment option, addressing the growing market demand.
- Deepening Strategic Partnership: This agreement not only continues the collaboration between Medtronic and Merit but also enhances Medtronic's leadership in the pain intervention field by incorporating Merit's proprietary technology, thereby diversifying its product portfolio.
- Long-term Vision: Paolo Di Vincenzo, president of Medtronic's Neuromodulation division, stated that the addition of this new product will further expand their world-leading position in pain interventions, aiming to provide more effective treatment options for patients and physicians.
See More
